Rovin Capital UT ADV Makes New $669,000 Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Rovin Capital UT ADV bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,999 shares of the medical research company's stock, valued at approximately $669,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC raised its holdings in shares of Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company's stock worth $173,773,000 after buying an additional 634,311 shares in the last quarter. Swedbank AB purchased a new position in Bio-Rad Laboratories during the first quarter valued at $1,824,000. Gabelli Funds LLC lifted its position in Bio-Rad Laboratories by 16.8% during the first quarter. Gabelli Funds LLC now owns 41,800 shares of the medical research company's stock valued at $14,457,000 after purchasing an additional 6,000 shares during the last quarter. Qsemble Capital Management LP bought a new stake in Bio-Rad Laboratories during the first quarter valued at about $567,000. Finally, SG Americas Securities LLC increased its holdings in Bio-Rad Laboratories by 289.7% in the first quarter. SG Americas Securities LLC now owns 6,792 shares of the medical research company's stock valued at $2,349,000 after buying an additional 5,049 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded down $3.62 during trading hours on Friday, hitting $369.25. 149,609 shares of the company traded hands, compared to its average volume of 200,399. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The firm's 50-day simple moving average is $338.51 and its 200-day simple moving average is $311.49. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period last year, the firm earned $2.33 earnings per share. The company's quarterly revenue was up 2.8% on a year-over-year basis. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

Insider Activity at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company's stock, valued at approximately $48,582.03. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the firm's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by insiders.

Analyst Ratings Changes

BIO has been the subject of several recent analyst reports. StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Royal Bank of Canada boosted their price objective on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price target for the company. Finally, Citigroup raised their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.